Inspyr Therapeutics, Inc.

Inspyr Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for neurological disorders and other complex diseases, emphasizing advanced treatment solutions that address significant unmet medical needs. Founded in 2003 and headquartered in Westlake Village, US, Inspyr Therapeutics specializes in biotechnology with a focus on therapies for complex medical conditions. The company has undergone strategic pivots over the years but specific details are not provided.

The founder's history and previous ventures are not mentioned. Inspyr Therapeutics has engaged in one deal, with the most recent funding round occurring on March 17, 2017, when it was the investment target for a total of USD 100 million in debt financing from Milost Global, Inc. Inspyr Therapeutics offers a range of innovative biotechnology products aimed at providing advanced therapeutic solutions for various medical conditions. The company focuses on developing treatments that improve patient outcomes in areas such as neurology and complex diseases.

Their services are targeted towards healthcare providers and institutions, ensuring that their offerings meet the specific needs of patients and healthcare systems alike. Inspyr Therapeutics reported an EBITDA of USD -610,000 for the most recent year, 2022. Their revenue model primarily revolves around partnerships and collaborations that support ongoing therapeutic development and commercialization efforts. Inspyr Therapeutics plans to leverage its recent financing of USD 100 million to advance its therapeutic pipeline and expand its reach into new markets.

The funding will support the development and launch of upcoming products aimed at treating neurological disorders. The company is targeting expansion into European and Asian markets by 2024, focusing on regions with significant unmet medical needs in the healthcare sector.